TTC23抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse adrenal gland and kidney tissue, Primary antibody: P08917(TTC23 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08917(TTC23 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08917(TTC23 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The TTC23 (Tetratricopeptide Repeat Domain 23) antibody is a tool used to study the TTC23 protein, encoded by the *TTC23* gene in humans. TTC23 belongs to a family of proteins containing tetratricopeptide repeat (TPR) domains, which mediate protein-protein interactions. While its precise biological role remains under investigation, TTC23 is implicated in cilia-related functions, potentially influencing ciliary structure or signaling pathways. Dysregulation of ciliary proteins is linked to developmental disorders and diseases, such as ciliopathies, making TTC23 a subject of interest in neurodevelopmental and genetic research.

Antibodies targeting TTC23 enable researchers to detect its expression, localization, and interactions in cellular and tissue contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore TTC23’s role in physiological and pathological processes. Recent studies suggest TTC23 may interact with proteins involved in intraflagellar transport (IFT), critical for cilia assembly and maintenance. Mutations in *TTC23* have been associated with neurological and renal abnormalities in animal models, highlighting its potential relevance in human diseases.

The development and validation of TTC23 antibodies contribute to elucidating molecular mechanisms underlying cilia dysfunction and may aid in identifying therapeutic targets for ciliopathies or other TTC23-associated conditions.